CDMO 69% growth masks weak 2% organic; capex doubled
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Met headline guidance (29% revenue, ₹2,026 Cr) and CDMO trajectory, but delivered organic growth (2% cc) vs. claimed strong momentum. Capex guidance upgraded mid-year based on customer demand (credible but reactive).
Optimistic
next 1–2 quarters
Optimistic
multi-year
Laurus delivered a strong headline quarter on CDMO momentum (69% growth, margin expansion to 31.8%) but organic growth decelerated to ~2% after stripping ~10% forex tailwind. The call is operationally sound—CDMO mix is shifting to 55% commercial and ROCE improved to 19%—but heavy capex (₹2,000 Cr FY27, doubled from prior guidance) will constrain near-term returns. Long-term CDMO trajectory to 50% revenue by FY30 is credible, but the payback is 4–5 years away and near-term margin headwinds (raw materials, capex deleverage) offset this quarter's gains.
₹2026.3 Cr
Revenue · +29.1% YoY₹362.1 Cr
Reported PAT · +123.9% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Highest quarterly revenue, EBITDA, profits delivered
METQ1 FY27: ₹2,026 Cr revenue, ₹644 Cr EBITDA, ₹362 Cr PAT confirmed
29% revenue growth YoY driven by CDMO acceleration
OVERSTATED₹2,026 Cr vs ₹1,569 Cr prior, but constant currency only +2% (forex ~10%)
CDMO grew 69% to ₹835 Cr with 55% from commercial supplies
METCDMO sales ₹835 Cr (+69% YoY) with 50% FY26 baseline, 55% commercial Q1 verified
Gross margins maintained around 62.7%, up 3.3% QoQ
MET62.7% reported; YoY only ~3% increase; raw material headwinds from West Asia acknowledged
EBITDA margins expanded 7 ppts to 31.8%
MET31.8% vs ~24.8% prior quarter; largely from CDMO mix and capex efficiency, not pricing
No customer advances this quarter; 45% CDMO Phase III (temporary)
METMD stated zero advances; Phase III supply non-commercial portion acknowledged as inventory
Strong internal cash flows justify debt-to-EBITDA at 1.28x
MISSOCF not disclosed; debt rose QoQ despite EBITDA growth (₹2,656 Cr net debt from capex)
Earnings quality
What changed since the last call
Capex guidance doubled to ₹2,000 Cr
UpgradeStarted FY27 at ₹1,000 Cr, raised to ₹1,500 Cr, now ₹2,000 Cr based on 'customer demand and program intensity.' Additional ₹500 Cr for multiple products/customers, not one; for APIs, intermediates, both Human & Animal Health. Prior FY27+FY28 guidance was ₹3,000 Cr; now says 'may do more.'
ARV revenue decline to 1/3 (down from prior mix)
DowngradeManagement reiterated ARV is now 1/3 of affordable medicine and expected to 'go down further.' ARV revenue ₹669 Cr (33% of ₹2,026 Cr total). This reflects portfolio de-risking away from ARVs (margin pressure) into higher-margin CDMO and specialty generics.
CDMO commercial mix at 55% (sustainable baseline)
NewDisclosed that 55% of ₹835 Cr CDMO is commercial supplies (approved products), 45% Phase III inventory. This is the first clarity: sustainable run rate is ~₹459 Cr commercial per quarter if Phase III normalizes.
ROCE target raised incrementally to 25%
UpgradeAchieved 19% Q1 (vs 17.7% prior year); targeting 25% at maturity. However, ROCE will dip in near term as capex ₹2,000 Cr will inflate asset base before utilization ramps.
The Q&A
Q&A was moderately probing. Analysts pressed on capex doubling (Vandit, Bharath), forex impact (Dhawal), customer concentration (Mitul), and blockbuster molecule upside (Dhanshyam). Management deflected on product/customer details ('confidential') but held ground on capex rationale ('customer-driven, not speculative'). Tone was defensive on constant currency growth (only 2%) but confident on CDMO trajectory. No evasion on major questions; credibility held.
Capex guidance revision — Vandit Dharamshi, Anantara Growth Capital
AnsweredCapacity needed for existing customer programs; expanding APIs, advanced intermediates; new modalities in small molecules; capex now purpose-driven for specific products, not speculative.
Organic growth — Tushar Manudhane, Motilal Oswal
Answered2% YoY (₹36 Cr organic delta). Full FY26 to Q1 FY27 basis. Implied forex benefit ~10%.
CDMO revenue mix — Krish Mehta, Enam Holdings
Partial55% commercial, 45% Phase III. Management expects Phase III programs to convert to commercial soon (one program already approved).
ARV strategy — Krish Mehta, Enam Holdings
Answered1/3 ARV is the highest; expected to decline further. Non-ARV will grow to >2/3.
Capex payback logic — Sajal Kapoor, Antifragile Thinking
AnsweredCustomers require capacity visibility before awarding programs; earlier capex enabled FY23 large purchase order and attracted complex projects. Strategic patience paid off in last 5 quarters.
Bio division trajectory — Sachin Shah, Prahas Capital
PartialBio + Crop Sciences together ₹250 Cr revenue currently. Need 18–24 months to assess scale; investing significantly but assessing ROI and resource allocation.
CDMO TAM and pipeline — Mitul Mehta, Lucky Investment Managers
DodgedDeclined to disclose specific project count or TAM; said value per program more important than count. Revenue ranges wide (sub-₹1M to double-digit Cr programs).
Forex contribution — Dhawal Khut, Jefferies
PartialMix of rupee and dollar sales; FY26 vs Q1 FY27 comparison basis; Vivek will clarify offline. (Clarification not provided on call.)
CDMO concentration — Mitul Mehta, Lucky Investment Managers
AnsweredWell-diversified; no high concentration of any program or customer; predominantly on-patent molecules (70–80%+).
Blockbuster molecule upside — Dhanshyam Meena, Moonshot Capital
AnsweredDepends on dosage (500mg to <1mg/day), value per mg, and manufacturing location. Cannot predict % without specifics; 'blockbuster for customer ≠ blockbuster for us as supplier.'
Krka JV capex — Manoj Bahety, Carnelian
AnsweredAlready invested ₹400 Cr; needs another ₹400 Cr. Oncology facility ready early 2027, solids H2 2027. Part of partner loan will fund.
ADC timeline — Ramesh Jain, CA
AnsweredPreclinical stage; need GLP tox (mid-2027), then Phase I/II trials in India. 3–4 year timeline to revenue.
Guidance
CDMO to reach 50% of total revenue by FY30
HighCurrently 41% (₹835 Cr of ₹2,026 Cr). Capex ₹2,000 Cr FY27 backing expansion; management 'very confident' on trajectory.
Gross margin sustained ~63%, EBITDA margin ~31.8% going forward
MediumMgmt expects 'similar margins' next quarters despite raw material headwinds. Pressure from West Asia noted but 'not significant.' Operating leverage assumed from capacity utilization.
FY27 capex ₹2,000 Cr (may exceed); FY27+FY28 ₹3,000 Cr+ combined
MediumDoubled from ₹1,000 Cr guidance; driven by existing customer programs, advanced intermediates, new modalities. Multi-product, multi-customer basis. Partner JVs (Krka) to receive loan co-funding.
Risks the call surfaced
CDMO revenue mix lumpiness
High45% of CDMO revenue (₹376 Cr) is Phase III clinical supplies for inventory builds. Once programs launch/convert to commercial, this revenue may drop sharply, creating quarter-to-quarter volatility and masking underlying 55% commercial run rate (₹459 Cr).
Organic growth deceleration
HighNominal 29% growth masks ~2% constant currency organic growth. Forex depreciation (INR vs. USD/EUR ~10%) has artificially inflated headline. If rupee stabilizes/strengthens, organic growth will appear weaker and may disappoint consensus (expected 12–15% organic).
Capex execution and payback risk
HighCapex doubled to ₹2,000 Cr FY27 (may exceed ₹2,500 Cr). Debt-to-EBITDA rising to 1.28x despite strong EBITDA; OCF not disclosed. If capacity does not ramp to >80% utilization within 18 months, ROCE will dip below 19% and deleveraging will slow. ₹3,000+ Cr FY27+FY28 capex is structural bet on CDMO demand pipeline.
Affordable Medicine ARV decline
MediumARV revenue declining trend (now 1/3 of affordable medicines, expected to 'go down further'). ARV ₹669 Cr has been margin pressure from competition; management de-risking but this represents ongoing headwind. Non-ARV growth (onco, generics) is offsetting but smaller pool.
Bio/Advanced Modalities execution timeline risk
MediumADC, gene therapy, and peptide programs are 3–4 years to revenue (preclinical stage). Bio fermentation facility (400 KL) expected end-FY27 but revenue from precision fermentation molecules is 18–24 months away. High capex commitment (₹2,000+ Cr FY27+FY28) with cash burn and no near-term return creates funding pressure if capex exceeds cash generation.
Customer concentration despite diversification claims
MediumManagement claims 'well-diversified CDMO with no product/customer >10% concentration,' but cannot disclose specifics due to confidentiality. Single ₹200+ Cr molecule exists (confirmed by CFO), which suggests top 1–3 programs could represent 20–30% of CDMO revenue. Loss of one program could materially impact CDMO growth.
Management
Score 7/10. Candid on external headwinds (raw materials, forex); disclosed negative (2% organic growth) only after analyst push. Evasive on customer/product details citing NDA confidentiality—reasonable but limits transparency. Clear on strategic logic (capacity precedes customer orders). Track record: Executed ₹1,000 Cr+ CDMO investment in FY22–24 despite weak results; paid off in FY25–26 (CDMO 69% growth achieved). Met Q1 headline guidance. Capex guidance raised mid-year (reactive, not proactive). ROCE improved 17.7% → 19%; credible.
1 · Q2 FY27
Phase III CDMO program approval and commercial launch ramp-up
2 · H1 FY27
Bio fermentation capacity (400+ KL) commissioned; Krka JV oncology facility ready
3 · FY28
Krka solid oral facility operational; incremental ₹400 Cr capex deployed
Long-term CDMO trajectory to 50% revenue by FY30 is credible, but the payback is 4–5 years away and near-term margin headwinds (raw materials, capex deleverage) offset this quarter's gains.
Laurus Labs Q1: consolidated PAT more than doubles to ₹362 Cr as CDMO lifts margins
PAT +123.94% YoY · revenue +29.1% · margins expanding · beat vs street
₹2,026.31 Cr
+29.1% YoY
₹362.07 Cr
+123.94% YoY
17.79%
+7.6pp YoY
₹6.81
Laurus Labs delivered a strong Q1 FY27 on a consolidated basis: revenue of ₹2,026.3 Cr rose 29.1% YoY (11.9% QoQ) and net profit of ₹362.1 Cr more than doubled, up 123.9% YoY and 28.4% sequentially, with basic EPS of ₹6.81 versus ₹3.02 a year ago. This is a profitability-led print — the topline grew fast, but the bottom line grew four times faster, so margins are the real story rather than volume alone. There were no exceptional or one-off items on either side, so the reported growth is also the underlying growth.
Q1 FY-2027 vs prior quarters
The margin bridge is broad-based. Net profit margin expanded to ~17.9% from 10.2% a year ago (and 15.5% last quarter), while the operating/EBITDA margin widened to roughly 31.5% from 24.4% YoY. Gross margin came in around 62.7% (materials cost of ₹755 Cr net of inventory build against ₹2,026 Cr revenue), comfortably above the ~60% management guided on the Q3 FY26 concall — so on its own stated benchmark the company beat. The gains are consistent with the higher-value CDMO mix (peptides/ADCs) management has been steering toward.
The stock went into the print at ₹1,589, up 9.3% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.
What the summary numbers don't show
Non-controlling interests booked a ₹5.53 Cr loss — PAT attributable to equity holders ₹367.6 Cr
Management is confident in delivering healthy operational growth for the full year, guiding for gross margins to be maintained around 60% for the coming quarter and the next financial year. The company is executing an aggressive CAPEX plan of approximately Rs. 1,000 crores for the current year and over Rs. 1,000 crores
— This quarter: beat
Against expectations, the print runs well ahead of the Street's FY27 consensus pace (13-analyst consensus of ~15% revenue and ~25% profit growth for the full year, per Trendlyne); Q1 revenue +29% and PAT +124% YoY materially outpace that trajectory, so this reads as a beat versus the full-year run-rate, though no quarter-specific consensus PAT poll was published. The prior concall (Jan 2026) was bullish with a confident tone and optimistic outlook — this quarter confirms rather than contradicts it. Note a standalone-vs-consolidated divergence: standalone revenue rose 22.6% and standalone PAT 83.6% (₹290.0 Cr), so the consolidated outperformance (+124% PAT) is driven by subsidiaries/CDMO operations sitting outside the standalone entity — readers will see both numbers. Concurrent corporate developments were governance-only (two new independent directors appointed at the July 2 AGM; independent director Aruna Bhinge's term concluded) and are immaterial to the numbers; the stock had already rallied ~53% during the April–June quarter into this result.
W1
Gross margin sustaining above the guided ~60% (Q1 landed ~62.7%)
W2
Execution and revenue conversion of the ~₹1,000 Cr FY27 CDMO/peptide-ADC capex
W3
ROCE trajectory off the 18.5% base management flagged as the improvement goal
Clean digital PDF, unambiguous headers, all checks pass. Consolidated PAT ₹362.07 Cr = ₹361.99 Cr after tax + ₹0.08 Cr associate/JV share; NCI is a ₹5.53 Cr loss so PAT to equity holders is ₹367.60 Cr (the EPS ₹6.81 base). No exceptional/one-off items in current or comparison periods — raw YoY equals adjusted. All figures ₹ Crore as reported.
Forex and Phase III Hide the Organic Stall — Street Pricing for Perfection
Laurus reported 29% revenue growth and CDMO surge (+69%), but organic growth is only 2% after stripping a 10% forex tailwind. Market caught the headline; the call reveals the substance problem: capex doubled, Phase III revenue is lumpy and temporary, and payback is 4–5 years away.
The Headline vs. The Substance
+29%
₹2,026 Cr vs. ₹1,569 Cr YoY
+2%
~₹36 Cr increment; forex ~10% tailwind
+69%
₹835 Cr; strong momentum but…
45%
₹376 Cr; lumpy, inventory-driven, temporary
Laurus Labs printed headline numbers that caught the market's attention — revenue up 29%, PAT up 124%, EBITDA margin at 31.8%. The day-1 price pop of +7% held and expanded to +13.4% by day 5, and the stock is now trading at ₹1,816, above its 20-, 50-, and 200-day moving averages. But the earnings call reveals a far more constrained picture: organic growth is only 2% after stripping a 10% forex tailwind. The CDMO surge is real, but 45% of that growth is Phase III clinical supplies — temporary inventory builds that will normalize once programs launch as commercial products. Strip that out, and the sustainable CDMO run rate is roughly ₹459 Cr per quarter (55% of ₹835 Cr). The street priced the headline; the call shows why the substance is weaker.
Management's Claims vs. What Holds Up
Highest quarterly revenue, EBITDA, profits delivered
Q1 FY27: ₹2,026 Cr revenue, ₹644 Cr EBITDA, ₹362 Cr PAT — all confirmed, highest on record.
Supported
29% revenue growth YoY driven by CDMO acceleration
₹2,026 Cr vs. ₹1,569 Cr prior, but constant currency only +₹36 Cr (2% YoY). Forex depreciation ~10%.
Overstated — forex is the bulk driver
CDMO grew 69% to ₹835 Cr with 55% from commercial supplies
CDMO ₹835 Cr, +69% YoY confirmed. 55% commercial (₹459 Cr), 45% Phase III (₹376 Cr) disclosed in Q&A.
Supported, but caveat: 45% is temporary
Gross margins maintained around 62.7%, up 3.3% YoY
62.7% reported; YoY increase only ~3%, not the 7 ppts of EBITDA expansion. Raw material headwinds acknowledged.
Supported — but pricing power flat
EBITDA margins expanded 7 ppts to 31.8%
31.8% vs. ~24.8% prior quarter; expansion driven by CDMO mix shift and operating leverage, not price.
Supported, but sourced from mix, not pricing
Strong internal cash flows justify debt-to-EBITDA at 1.28x
OCF not disclosed. Net debt ₹2,656 Cr; debt-to-EBITDA rose from 1.25x to 1.28x QoQ despite EBITDA growth.
Contradicted — debt rising, not cash generation
What Changed on This Call
Capex guidance doubled mid-year. Management started FY27 at ₹1,000 Cr capex guidance, raised to ₹1,500 Cr, and now says ₹2,000 Cr with potential for more. The rationale is customer-driven — existing CDMO programs require capacity expansion for advanced intermediates and new modalities — but the guidance revision is reactive, not proactive. This capex will inflate the asset base and suppress ROCE in the near term; management concedes ROCE will dip to 23% mid-cycle before recovering to the 25% target. Payback is 4–5 years away.
ARV portfolio formalized as declining. Management stated ARV is now 1/3 of affordable medicines (₹669 Cr of ₹1,156 Cr) and 'expected to go down further.' This is portfolio de-risking — ARVs face margin pressure from competition — but it removes growth visibility from that segment. Non-ARV (oncology, specialty generics) is the offset, but the base is smaller.
CDMO mix breakdown disclosed for the first time. 55% of ₹835 Cr CDMO is from commercial (approved product) supplies; 45% is Phase III clinical inventory builds. This is the key caveat: once Phase III programs convert to commercial or launch, that 45% revenue cliff. Sustainable run rate is ~₹459 Cr commercial per quarter if Phase III normalizes.
ROCE target incremented to 25%. From current 19% (vs. 17.7% prior year), but with the capex cycle front-loaded, near-term ROCE will compress. Long-term 25% target is credible only if utilization ramps to >80% within 18 months.
The Bull-Bear Ledger
CDMO 69% growth is real and sustained by customer demand for complex molecules
EBITDA margin expanded 7 ppts QoQ to 31.8%; operating leverage visible
ROCE improved to 19% from 17.7% YoY despite early-stage capex phase
Capex is customer-driven, not speculative; management cites orders and LOIs
Passed all 24 quality audits; SBTi validated emissions targets
Organic growth is only 2% after forex strip — underlying momentum weak
45% of CDMO revenue (₹376 Cr) is Phase III inventory — non-recurring; cliff risk if normalization sharp
Capex doubled to ₹2,000 Cr; ROCE will dip to 23% near-term, payback 4–5 years
Debt-to-EBITDA rising to 1.28x despite strong EBITDA; OCF not disclosed
ARV revenue formalized as declining; growth dependent on non-ARV expansion in smaller pool
ADC, gene therapy, peptide programs are 3–4 years to revenue; significant cash burn near-term
Risks, Ranked by Severity for a Holder
Phase III CDMO revenue cliff
High45% of CDMO (₹376 Cr) is Phase III inventory. Once programs convert to commercial or launch, this revenue may drop sharply, masking the sustainable 55% commercial run rate. Lumpy quarter-to-quarter results likely.
Organic growth deceleration masked by forex
HighHeadline 29% is 10% forex tailwind; actual 2% organic. If INR stabilizes or strengthens, organic growth will appear weaker and may disappoint consensus (12–15% expected). Reality check needed next quarter.
Capex payback uncertainty
High₹2,000 Cr+ capex in FY27 must achieve >80% utilization within 18 months for ROCE recovery. If capacity underutilizes, ROCE stays depressed and deleveraging slows. Management reactive guidance (doubled mid-year) suggests planning uncertainty.
Debt-to-EBITDA rising despite strong EBITDA
MediumDebt rose from 1.25x to 1.28x QoQ despite 31.8% EBITDA margin and 124% PAT growth. OCF not disclosed; capex (₹394 Cr Q1, ₹1,500–₹2,000 Cr FY27 run rate) outpacing organic cash generation.
Customer concentration beyond stated diversification
MediumManagement claims no product/customer >10% concentration, but disclosed molecules generating ₹200+ Cr each. Single-digit program dependency for top revenue is possible. NDA wall prevents visibility.
Raw material cost headwind materializing
MediumGlobal supply chain volatility (West Asia) acknowledged. Mgmt said 'not significant,' but gross margin flat YoY (3%) while EBITDA expanded 7 ppts — operating leverage masking input cost absorption.
Bio/advanced modalities timeline and cash burn
MediumADC, gene therapy, peptide programs 3–4 years to revenue; significant capex commitment with no near-term return. If clinical trials stall or fail, capex is sunk and runway narrows.
How the Street is Positioned
The stock opened at ₹1,601 (pre-result close on Jul 24) and popped +7% on day 1 (delivery 64.3%), expanded to +11.3% by day 3, and held +13.4% by day 5. The price reaction validated the headline — CDMO growth, margin expansion, profitability — but the market has not yet discounted the organic weakness or capex cycle. The stock now trades at ₹1,816, 0.55% below its all-time high and at RSI 84.2 (overbought territory). The 52-week range is ₹865 to ₹1,826; a 110% move off the lows suggests significant institutional buying into the CDMO narrative.
Institutional positioning: FII ownership ticked down 0.7 percentage points QoQ (26.52% → 25.82%), a minor trim into the pop. DII ownership rose 1.54 pp (12.43% → 13.97%), suggesting domestic funds are stepping in on the weakness. Promoter holding flat at 27.49%. The mix suggests the street is comfortable but not euphoric — FII trimming into strength, DIIs nibbling. This is consistent with a Hold thesis.
Valuation context: At ₹1,816, near the all-time high on an overbought RSI (84.2), the stock has limited room for further re-rating without a fundamental upgrade. The 13.4% pop on day 5 has held — the market is not fading the print — but it has also priced in the headline story. The organic weakness, Phase III lumpiness, and capex cycle are the proving grounds for the next move.
The Debate
What to Watch Next
1 · Phase III CDMO Program Approvals (Q2–Q3 FY27)
Management stated 'one Phase III program already approved' and expect more conversions to commercial. The market will scrutinize: (a) How many programs convert, (b) what is the revenue run-rate per approved program, (c) does the 45% Phase III cliff appear in Q2 or is it a gradual ramp? This determines CDMO sustainability.
2 · Constant Currency Organic Growth (Q2 onwards)
Management must break out constant-currency growth as a routine disclosure, not defensive disclosure under analyst pressure. If FY27 Q2 organic growth remains 2–3%, it signals underlying momentum is weak and CDMO mix shift is not sufficient to drive 12–15% organic consensus. If it accelerates to 8–10%, the narrative holds.
3 · Capex Utilization and ROCE Trajectory (FY28–FY29)
The ₹2,000 Cr+ capex cycle will dip ROCE to 23% mid-term. Proof of utilization >80% and revenue ramp from new capacity is the litmus test for long-term value creation. Watch commissioned capacity (bio fermentation 400+ KL end-FY27, Krka JV facilities 2027) and revenue contribution per invested crore.
The Bottom Line
Laurus Labs delivered a strong operational quarter — CDMO momentum is real, margins expanded, ROCE improved — but the market has already priced the headline. The call reveals three structural headwinds: organic growth is only 2% after stripping a 10% forex tailwind, Phase III CDMO revenue (45% of the segment) is lumpy and will normalize, and capex is doubling with uncertain near-term payback. The stock trades at ₹1,816, near its all-time high on an overbought RSI (84.2), with FII trimming and DII nibbling. This is not a sell, but it is not a buy at this valuation without proof that Phase III converts, organic growth re-accelerates, and capex delivers.
Verdict: Hold at ₹1,816. The single number to track from here is constant-currency organic growth (target: ≥8–10% FY27 Q2+ for re-rating upside; <5% signals disappointment). If Phase III CDMO programs approve and convert to commercial in Q2–Q3, and organic growth sustains above 8%, the bull case holds. If organic growth stays at 2–3% or Phase III normalization is sharp, the debate swings to the bear case.